Systemic Therapy Update on
177
Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A
JCO Oncol Pract
.
2023 Mar;19(3):132-135.
doi: 10.1200/OP.22.00753.
Epub 2023 Jan 24.
Authors
Rohan Garje
1
,
Thomas A Hope
2
,
R Bryan Rumble
3
,
Rahul A Parikh
4
;
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Guideline Expert Panel
Affiliations
1
Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
2
University of California, San Francisco, San Francisco, CA.
3
American Society of Clinical Oncology, Alexandria, VA.
4
University of Kansas Medical Center, Kansas City, KS.
PMID:
36693228
DOI:
10.1200/OP.22.00753
No abstract available
MeSH terms
Dipeptides
Humans
Lutetium*
Male
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant* / pathology
Substances
PSMA-617
Lutetium
Prostate-Specific Antigen
Dipeptides